Form 4: X4 Pharmaceuticals Director de Craecker Francoise Receives 45,000 Restricted Stock Units

Director de Craecker Francoise of X4 Pharmaceuticals, Inc. was granted 45,000 restricted stock units (RSUs) as an annual award for board service.

Summary

• Francoise de Craecker, a director at X4 Pharmaceuticals, Inc., received 45,000 restricted stock units (RSUs) on June 10, 2024.
• These RSUs are an annual award for her service on the Board of Directors.
• The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date.
• The RSUs will vest in full upon the occurrence of a change in control of the Issuer.
• Following this transaction, de Craecker directly owns 96,667 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and aligns the director's interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting conditions incentivize continued service and a focus on long-term value creation.

Future Outlook

The vesting of the RSUs is contingent upon continued board service or a change in control of the Issuer.

Industry Context

Grants of restricted stock units to board members are a common practice to align their interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• The grant of RSUs aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholders.
• The vesting conditions incentivize continued service and a focus on long-term value creation.

Key Dates